Auris Medical Holding Ltd (NASDAQ:EARS) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 163,300 shares, a decline of 5.9% from the July 31st total of 173,600 shares. Based on an average daily volume of 186,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 10.4% of the company’s shares are short sold.

NASDAQ:EARS traded up $0.03 on Monday, reaching $3.05. The company’s stock had a trading volume of 1,568 shares, compared to its average volume of 98,118. Auris Medical has a 12-month low of $2.41 and a 12-month high of $39.40. The firm has a market cap of $5.63 million, a price-to-earnings ratio of -0.20 and a beta of -0.49. The stock has a 50 day moving average price of $2.75 and a 200 day moving average price of $2.10.

A hedge fund recently bought a new stake in Auris Medical stock. Jane Street Group LLC acquired a new stake in Auris Medical Holding Ltd (NASDAQ:EARS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,934 shares of the biotechnology company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.58% of Auris Medical at the end of the most recent quarter. Institutional investors and hedge funds own 10.25% of the company’s stock.

Separately, Zacks Investment Research downgraded Auris Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 22nd.

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Stochastic Momentum Index (SMI)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.